NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed Refractory Myeloma

• NCT05172596: Phase 2: PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cells, manufactured with a new process. CAR-T cells will be investigated as a single agent in relapsed and refractory multiple myeloma

Sponsor

Novartis Pharmaceuticals

---

ClinicalTrials.gov Identifier: NCT05172596

Official Title: Phase II, Open Label, Study of PHE885, a B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patients With Relapsed and Refractory Multiple Myeloma

First Posted : December 29, 2021

Click here to see details on ClinicalTrials.gov

---

Biological: PHE885

BCMA-directed Autologous CAR-T Cells PHE885

Autologous Anti-BCMA CAR T-cells PHE885 (Code C174124)

Autologous Anti-BCMA CAR T-cells PHE885

Autologous BCMA-specific CAR T-cells PHE885

BCMA-directed Autologous CAR-T Cells PHE885

PHE 885

PHE-885

PHE885

---

Locations

Australia, Melbourne

Singapore